BioMark Diagnostics Expands Research Development in Quebec
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship. "This move highlights BioMark's focus on diagnostic development and technological...
2020-08-13 8:30 AM EDT
BioMark's Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that its affiliated company, Bio-Stream Diagnostics Inc., will be working with University of Qatar's Dr. Somaya Al-Maadeed in the development of its novel COVID-19-detection method, leveraging new generation Raman spectroscopy and the power of machine learning. Raman spectroscopy is a spectroscopic technique typically used to determine...
2020-07-21 8:30 AM EDT
BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark"
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark". The term "BioMark" was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations. Biomarker testing is...
2020-07-16 8:30 AM EDT
BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer diagnostic platform that repurposes a U.S. Food and Drug Administration (FDA) off...
2020-06-23 8:30 AM EDT
BioMark Receives European Patent for Cancer Diagnostic
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the company has been granted a patent titled "A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE." The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase activity. The patent will cover a novel approach to diagnosing...
2020-06-18 8:30 AM EDT
Bio Stream Diagnostics Inc. Selected for CDL Rapid Response Innovation Program
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its affiliated company, Bio Stream Diagnostics Inc., was selected to participate in the global academic science and tech startup program Creative Destruction Lab's (CDL) recent dedicated Recovery program. CDL Recovery is designed to help turn science and research work into scalable products and services to address the...
2020-06-16 8:30 AM EDT
BioMark Diagnostics Inc. Clarifies Prior Disclosure
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated by the Company on June 10, 2020 with respect to the formation of Bio Stream Diagnostics Inc., a new...
2020-06-11 5:37 PM EDT
BioMark Diagnostics Forms New Company, Bio Stream Diagnostics Inc., for '30-Second' COVID-19 Screening
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) - BioMark Diagnostics Inc.(CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today that the Company has partnered with Stream.ML and Merogenomics to form Bio Stream Diagnostics Inc., a new company, focused on providing low-cost COVID-19 detection in less-than-30...
2020-06-10 8:30 AM EDT
BioMark Announces Filing of Amended and Restated MD&A for the Three and Nine Months Ended December 31, 2019
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure. BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark")announced it has amended and restated its interim management discussion and analysis (the "Interim MD&A") for the three and nine months ending December 31, 2019. The Interim MD&A has been amended to clarify and expand...
2020-05-29 4:30 PM EDT
BioMark's Liquid Biopsy Assay Levering Metabolomics Demonstrates Strong Performance for Early Lung Cancer Detection
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC PINK: BMKDF) ("BioMark") is pleased to announce that the article "A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection" has been published in the peer-reviewed journal Cancers, validating BioMark's technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test. Rashid Bux, President and CEO, says, "This...
2020-03-24 6:30 AM EDT
BioMark Diagnostics Advanced Raman Spectrometer Could Potentially Serve as Complementary Detection Tool for COVID -19 / Coronavirus
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today following their annual technology meeting that their Advanced Raman Spectrometer might have potential to be modified and reconfigured for use in the detection of certain pathogens and...
2020-03-16 8:30 AM EDT